<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36736291</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>SYF2 suppression mitigates neurodegeneration in models of diverse forms of ALS.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>187.e14</EndPage><MedlinePgn>171-187.e14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2023.01.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(23)00005-X</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by many diverse genetic etiologies. Although therapeutics that specifically target causal mutations may rescue individual types of ALS, such approaches cannot treat most patients since they have unknown genetic etiology. Thus, there is a critical need for therapeutic strategies that rescue multiple forms of ALS. Here, we combine phenotypic chemical screening on a diverse cohort of ALS patient-derived neurons with bioinformatic analysis of large chemical and genetic perturbational datasets to identify broadly effective genetic targets for ALS. We show that suppressing the gene-encoding, spliceosome-associated factor SYF2 alleviates TDP-43 aggregation and mislocalization, improves TDP-43 activity, and rescues C9ORF72 and causes sporadic ALS neuron survival. Moreover, Syf2 suppression ameliorates neurodegeneration, neuromuscular junction loss, and motor dysfunction in TDP-43 mice. Thus, suppression of spliceosome-associated factors such as SYF2 may be a broadly effective therapeutic approach for ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Linares</LastName><ForeName>Gabriel R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yichen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Wen-Hsuan</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>AcuraStem Incorporated, Monrovia, CA 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin-Sigler</LastName><ForeName>Jasper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendonca</LastName><ForeName>Stacee</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AcuraStem Incorporated, Monrovia, CA 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AcuraStem Incorporated, Monrovia, CA 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eoh</LastName><ForeName>Yunsun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Wenxuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yi-Hsuan</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorjsuren</LastName><ForeName>Nomongo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Shu-Ting</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Johnny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, CA 94158, USA; Bakar Computational Health Sciences Institute, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Joscany</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chickering</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tze-Yuan</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>SVision LLC, Bellevue, WA 98006, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chi-Chou</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>SVision LLC, Bellevue, WA 98006, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shih-Jong James</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>SVision LLC, Bellevue, WA 98006, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Hao-Jen</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bach</LastName><ForeName>Kieu-Tram</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Kamden</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanyam</LastName><ForeName>Vishvak</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, CA 94158, USA; Bakar Computational Health Sciences Institute, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenfeld</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Loma Linda University, Loma Linda, CA 92350, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alworth</LastName><ForeName>Samuel V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>AcuraStem Incorporated, Monrovia, CA 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodarzi</LastName><ForeName>Hani</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, CA 94158, USA; Bakar Computational Health Sciences Institute, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichida</LastName><ForeName>Justin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA 90033, USA; Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA. Electronic address: ichida@usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS131409</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097850</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS077435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R44 NS097094</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC015530</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS077435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SYF2</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">androgens</Keyword><Keyword MajorTopicYN="N">connectivity map</Keyword><Keyword MajorTopicYN="N">drug screen</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cells</Keyword><Keyword MajorTopicYN="N">nineteen complex</Keyword><Keyword MajorTopicYN="N">norgestrel</Keyword><Keyword MajorTopicYN="N">spliceosome</Keyword></KeywordList><CoiStatement>Declaration of interests J.K.I. and S.A. are co-founders of AcuraStem, Inc. S.A., W.-H.C., S.M., and S.H. are employees of AcuraStem, Inc. J.K.I. is a co-founder of Modulo Bio, serves on the scientific advisory boards of AcuraStem, Spinogenix, Synapticure, and Vesalius Therapeutics, and is employed by BioMarin Pharmaceutical. H.G. is a co-founder of Exai Bio and Vevo Therapeutics and serves on the scientific advisory boards of Exai Bio and Verge Genomics. J.K.I. and G.R.L. are inventors on a patent application (PCT/US2021/014541) that has been filed related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36736291</ArticleId><ArticleId IdType="mid">NIHMS1867546</ArticleId><ArticleId IdType="pmc">PMC10062011</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2023.01.005</ArticleId><ArticleId IdType="pii">S1934-5909(23)00005-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, and Anthony Akkari P (2019). ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Frontiers in Neuroscience 13. 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlstr&#xf8;m L, Wiethoff S, and Houlden H (2017). Genetics of neurodegenerative diseases: an overview. Handb. Clin. Neurol 145, 309&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">28987179</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, et al. (2017). Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med 377, 1723&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, et al. (2020). Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med 383, 109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Hung S-T, Rocha G, Lin S, Linares GR, Staats KA, Seah C, Wang Y, Chickering M, Lai J, et al. (2019). Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. JCI Insight 5. 10.1172/jci.insight.127736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.127736</ArticleId><ArticleId IdType="pmc">PMC6693831</ArticleId><ArticleId IdType="pubmed">31310593</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, Li Y, Chang W-H, Hung S-T, Hendricks E, Linares GR, Wang Y, Son EY, et al. (2018). Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med 24, 313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, et al. (2018). Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell 173, 958&#x2013;971.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, Robinson AC, Liu X, Wu D, Troakes C, Rollinson S, Masuda-Suzukake M, Suzuki G, Nonaka T, Shi J, et al. (2016). Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathol. Appl. Neurobiol 42, 242&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832296</ArticleId><ArticleId IdType="pubmed">26538301</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, and Finkbeiner S (2010). Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci 30, 639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, and Rousseaux MWC (2020). The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener 15, 45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi P (2002). Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim. Biophys. Acta 1587, 326&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084475</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips A, Demarest K, Hahn DW, Wong F, and McGuire JL (1990). Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 41, 399&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">2335104</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RC, Singer AC, and Edgren RA (1979). The biological activities of norgestrel and its enantiomers. Int. J. Fertil 24, 39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">37178</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler J (2011). Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance? Br. J. Cancer 104, 1059&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068499</ArticleId><ArticleId IdType="pubmed">21364577</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwain IH, and Yen SS (1999). Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 140, 3843&#x2013;3852.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, Xie Q, Perkins R, Owens W, and Sheehan DM (2003). Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem. Res. Toxicol 16, 1338&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">14565775</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, Johnston SE, Vrcic A, Wong B, Khan M, et al. (2017). The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med 23, 405&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568558</ArticleId><ArticleId IdType="pubmed">28388612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, and Santoro N (2014). Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab 99, 3489&#x2013;3510.</Citation><ArticleIdList><ArticleId IdType="pubmed">25279570</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell CS, Ben-Yehuda S, Dix I, Kupiec M, and Beggs JD (2000). Functional analyses of interacting factors involved in both pre-mRNA splicing and cell cycle progression in Saccharomyces cerevisiae. RNA 6, 1565&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370026</ArticleId><ArticleId IdType="pubmed">11105756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Yehuda S, Dix I, Russell CS, McGarvey M, Beggs JD, and Kupiec M (2000). Genetic and physical interactions between factors involved in both cell cycle progression and pre-mRNA splicing in Saccharomyces cerevisiae. Genetics 156, 1503&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461362</ArticleId><ArticleId IdType="pubmed">11102353</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Yan C, Hang J, Finci LI, Lei J, and Shi Y (2017). An Atomic Structure of the Human Spliceosome. Cell 169, 918&#x2013;929.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">28502770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg R, McGrail JC, and O&#x2019;Keefe RT (2010). The function of the NineTeen Complex (NTC) in regulating spliceosome conformations and fidelity during pre-mRNA splicing. Biochem. Soc. Trans 38, 1110&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234902</ArticleId><ArticleId IdType="pubmed">20659013</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Uribe J, Aguill&#xf3;n D, Cochran JN, Giraldo M, Madrigal L, Killingsworth BW, Singhal R, Labib S, Alzate D, Velilla L, et al. (2022). A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects. Genome Med 14, 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8902761</ArticleId><ArticleId IdType="pubmed">35260199</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, Hadano S, Aoki M, Saya H, Sobue G, et al. (2018). Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med 24, 1579&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Cao M, Zheng H, Tan X, Li L, Cui G, Xu J, Cao J, Ke K, and Wu Q (2014). Upregulation of SYF2 is associated with neuronal apoptosis caused by reactive astrogliosis to neuroinflammation. J. Neurosci. Res 92, 318&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">24301298</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS, Troost D, Kretzschmar HA, Trojanowski JQ, et al. (2009). Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117, 137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z &#x2018;ev, Guo, L., Shorter, J., Da Cruz, S., and Cleveland, D.W. (2019). Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron 102, 339&#x2013;357.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, et al. (2019). Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci 22, 180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, et al. (2019). ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci 22, 167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracha D, Walls MT, Wei M-T, Zhu L, Kurian M, Avalos JL, Toettcher JE, and Brangwynne CP (2019). Mapping Local and Global Liquid Phase Behavior in Living Cells Using Photo-Oligomerizable Seeds. Cell 176, 407.</Citation><ArticleIdList><ArticleId IdType="pubmed">30633909</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, Copley KE, Hurtle B, Portz B, Pyles NJ, et al. (2019). RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron 102, 321&#x2013;338.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, Jackson KL, Arora A, Weskamp K, Tank EM-H, Li X, Miguez R, Dayton RD, Tamir S, Klein RL, et al. (2018). TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci. Rep 8, 4606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Funk C, Abou-Ajram C, Hutten S, Funk EBE, Kehlenbach RH, Bailer SM, and Dormann D (2018). Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci. Rep 8, 7084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Ca&#x11f;atay T, Fung HYJ, Li YC, Chook YM, and Thomas PJ (2018). Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci. Rep 8, 7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Love DC, Sweitzer TD, and Hanover JA (1998). Reconstitution of HIV-1 rev nuclear export: independent requirements for nuclear import and export. Proc. Natl. Acad. Sci. U. S. A 95, 10608&#x2013;10613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27942</ArticleId><ArticleId IdType="pubmed">9724751</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam SA (2016). Nuclear Protein Transport in Digitonin Permeabilized Cells. Methods Mol. Biol 1411, 479&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">27147060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, and Wong PC (2015). TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, McKeever PM, Lau A, and Robertson J (2019). Synaptic localization of C9orf72 regulates post-synaptic glutamate receptor 1 levels. Acta Neuropathol Commun 7, 161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813971</ArticleId><ArticleId IdType="pubmed">31651360</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins EM, Burr K, Banerjee P, Mehta AR, Dando O, Selvaraj BT, Suminaite D, Nanda J, Henstridge CM, Gillingwater TH, et al. (2021). Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction. Mol. Neurodegener 16, 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931347</ArticleId><ArticleId IdType="pubmed">33663561</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen BK, Schuldi MH, McAvoy K, Russell KA, Boehringer A, Curran BM, Krishnamurthy K, Wen X, Westergard T, Ma L, et al. (2020). Synaptic dysfunction induced by glycine&#x2010;alanine dipeptides in C9orf72&#x2010; ALS / FTD is rescued by SV 2 replenishment. EMBO Molecular Medicine 12. 10.15252/emmm.201910722.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201910722</ArticleId><ArticleId IdType="pmc">PMC7207170</ArticleId><ArticleId IdType="pubmed">32347002</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Pan YE, Giacomotto J, and Patten SA (2021). Reduced C9orf72 function leads to defective synaptic vesicle release and neuromuscular dysfunction in zebrafish. Commun Biol 4, 792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233344</ArticleId><ArticleId IdType="pubmed">34172817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini E, Rabinovich A, Iserte J, Yanovsky M, and Chernomoretz A (2021). Corrigendum to: ASpli: Integrative analysis of splicing landscapes through RNA-Seq assays. Bioinformatics 10.1093/bioinformatics/btab345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab345</ArticleId><ArticleId IdType="pubmed">34109387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, Briner A, Rodriguez CM, Guo C, Akiyama T, et al. (2022). TDP-43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature 603, 124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A-L, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, Bampton A, Lee FCY, Masino L, Qi YA, et al. (2022). TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Konopka A, Soo KY, Ito D, and Atkin JD (2017). The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet 26, 2882&#x2013;2896.</Citation><ArticleIdList><ArticleId IdType="pubmed">28481984</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade NS, Ramic M, Esanov R, Liu W, Rybin MJ, Gaidosh G, Abdallah A, Del&#x2019;Olio S, Huff TC, Chee NT, et al. (2020). Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Mol. Neurodegener 15, 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041170</ArticleId><ArticleId IdType="pubmed">32093728</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Chu PC, Lee L, Lien HW, Lin TL, and Fan CC, Chi P, Huang CJ, Chang MS (2012a) Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response. PLoS One</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308990</ArticleId><ArticleId IdType="pubmed">22448250</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick-de Groote C, Van Broeckhoven C, and Kumar-Singh S (2010). TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences 107, 3858&#x2013;3863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang A, Yang X, Chen H, Qin B, Zhu M, Dai M, Zhu R, and Liu X (2015). Upregulation of SYF2 Relates to Retinal Ganglion Cell Apoptosis and Retinal Glia Cell Proliferation After Light-Induced Retinal Damage. J. Mol. Neurosci 56, 480&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">25944718</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo Y-E, and Ko C-P (2012). Dihydrotestosterone ameliorates degeneration in muscle, axons and motoneurons and improves motor function in amyotrophic lateral sclerosis model mice. PLoS One 7, e37258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351454</ArticleId><ArticleId IdType="pubmed">22606355</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivekananda U, Manjalay Z-R, Ganesalingam J, Simms J, Shaw CE, Leigh PN, Turner MR, and Al-Chalabi A (2011). Low index-to-ring finger length ratio in sporadic ALS supports prenatally defined motor neuronal vulnerability. J. Neurol. Neurosurg. Psychiatry 82, 635&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">21551173</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas PS, Fraley GS, Damien V, Woodke LB, Zapata F, Sopher BL, Plymate SR, and La Spada AR (2006). Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. Hum. Mol. Genet 15, 2225&#x2013;2238.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772330</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C-H, Chu P-C, Lee L, Lien H-W, Lin T-L, Fan C-C, Chi P, Huang C-J, and Chang M-S (2012). Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response. PLoS One 7, e33538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308990</ArticleId><ArticleId IdType="pubmed">22448250</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Weisburd B, Thomas B, Solomonson M, Ruderfer DM, Kavanagh D, Hamamsy T, Lek M, Samocha KE, Cummings BB, et al. (2017). The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res 45, D840&#x2013;D845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210650</ArticleId><ArticleId IdType="pubmed">27899611</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K-I, et al. (2011). A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z-W, Chen H, Liu H, Lu J, Qian K, Huang C-L, Zhong X, Fan F, and Zhang S-C (2015). Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat. Commun 6, 6626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4375778</ArticleId><ArticleId IdType="pubmed">25806427</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandopulle MS, Prestil R, Grunseich C, Wang C, Gan L, and Ward ME (2018). Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr. Protoc. Cell Biol 79, e51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993937</ArticleId><ArticleId IdType="pubmed">29924488</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z. &#x2018;ev, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, et al. (2019). Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci 22, 180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra San Juan I, Nash LA, Smith KS, Leyton-Jaimes MF, Qian M, Klim JR, Limone F, Dorr AB, Couto A, Pintacuda G, et al. (2022). Loss of mouse Stmn2 function causes motor neuropathy. Neuron 110, 1671&#x2013;1688.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9119928</ArticleId><ArticleId IdType="pubmed">35294901</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, and Shi W (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923&#x2013;930. 10.1093/bioinformatics/btt656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, and Anders S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>